DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December

by · The Markets Daily

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, an increase of 28.4% from the November 30th total of 151,500 shares. Based on an average daily trading volume, of 87,500 shares, the days-to-cover ratio is currently 2.2 days.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $5.34 on Tuesday. The firm has a fifty day moving average of $4.80 and a 200 day moving average of $4.04. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.41. The firm has a market capitalization of $228.34 million, a PE ratio of -9.54 and a beta of 1.51.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

Get Our Latest Research Report on DiaMedica Therapeutics

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics in the 2nd quarter worth approximately $87,000. Blue Trust Inc. purchased a new position in shares of DiaMedica Therapeutics during the third quarter worth approximately $185,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $40,000. Finally, Geode Capital Management LLC boosted its stake in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after purchasing an additional 70,070 shares in the last quarter. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

Featured Stories